Yu Ishizuya

1.2k total citations
36 papers, 402 citations indexed

About

Yu Ishizuya is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Yu Ishizuya has authored 36 papers receiving a total of 402 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 14 papers in Surgery and 14 papers in Oncology. Recurrent topics in Yu Ishizuya's work include Bladder and Urothelial Cancer Treatments (12 papers), Prostate Cancer Treatment and Research (9 papers) and Renal cell carcinoma treatment (8 papers). Yu Ishizuya is often cited by papers focused on Bladder and Urothelial Cancer Treatments (12 papers), Prostate Cancer Treatment and Research (9 papers) and Renal cell carcinoma treatment (8 papers). Yu Ishizuya collaborates with scholars based in Japan, United States and Germany. Yu Ishizuya's co-authors include Norio Nonomura, Atsunari Kawashima, Motohide Uemura, Taigo Kato, Kazutoshi Fujita, Takeshi Ujike, Yujiro Hayashi, Cong Wang, Koji Hatano and Kosuke Nakano and has published in prestigious journals such as Scientific Reports, Biochemical and Biophysical Research Communications and British Journal of Cancer.

In The Last Decade

Yu Ishizuya

32 papers receiving 394 citations

Peers

Yu Ishizuya

PRM

ONCOL

SURGE

Yongliang Sun China

Annette M. Lim Australia

Guillermo de Velasco Spain

Evan Gomes-Giacoia United States

Chunfu Zhu China

Renpei Kato Japan

Takenori Uehara Japan

Daniel Pinďák Slovakia

Angela L. McCleary‐Wheeler United States

Yongliang Sun China

Yu Ishizuya

123 ×0.7

108 ×0.7

93 ×0.6

PRM

121 ×1.0

ONCOL

211 ×2.0

SURGE

Citations per year, relative to Yu Ishizuya Yu Ishizuya (= 1×) peers Yongliang Sun

Countries citing papers authored by Yu Ishizuya

Since Specialization

Citations

This map shows the geographic impact of Yu Ishizuya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu Ishizuya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu Ishizuya more than expected).

Fields of papers citing papers by Yu Ishizuya

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu Ishizuya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu Ishizuya. The network helps show where Yu Ishizuya may publish in the future.

Co-authorship network of co-authors of Yu Ishizuya

This figure shows the co-authorship network connecting the top 25 collaborators of Yu Ishizuya. A scholar is included among the top collaborators of Yu Ishizuya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu Ishizuya. Yu Ishizuya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ishizuya, Yu, Atsunari Kawashima, Yutong Liu, et al.. (2025). FAN score predicts prognosis after platinum-based first-line chemotherapy in patients with metastatic urothelial carcinoma. Scientific Reports. 15(1). 4640–4640. 1 indexed citations

Yamamoto, Yoshiyuki, Atsunari Kawashima, Kosuke Nakano, et al.. (2025). Comparative Outcomes of Adjuvant Chemotherapy and Immunotherapy After Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Multicenter Retrospective Study. JU Open Plus. 3(11).

Hatano, Koji, Shinichiro Tahara, Yu Ishizuya, et al.. (2025). Cancer genome profiling of prostate cancer identifies a patient with a novel EFNA1–NTRK1 fusion gene. International Cancer Conference Journal. 14(3). 296–301.

Kato, Taigo, Yu Ishizuya, Takuji Hayashi, et al.. (2025). PARP Inhibitors in Genitourinary Cancer: A New Paradigm Beyond Prostate Cancer. International Journal of Urology. 32(9). 1091–1101.

Kawashima, Atsunari, Yu Ishizuya, Yoshiyuki Yamamoto, et al.. (2024). Recent developments and future directions of first-line systemic therapy combined with immunotherapy for advanced or metastatic urothelial carcinoma: a historical perspective on treatment evolution. International Journal of Clinical Oncology. 29(8). 1096–1104. 4 indexed citations

Hatano, Koji, Yutong Liu, Akinaru Yamamoto, et al.. (2024). Cumulative incidence and risk factors for medication-related osteonecrosis of the jaw during long-term prostate cancer management. Scientific Reports. 14(1). 13451–13451. 4 indexed citations

Yamamichi, Gaku, Taigo Kato, Noriaki Arakawa, et al.. (2024). GDF15 propeptide promotes bone metastasis of castration-resistant prostate cancer by augmenting the bone microenvironment. Biomarker Research. 12(1). 147–147. 3 indexed citations

Nagahara, Akira, Yu Ishizuya, Yoshiyuki Yamamoto, et al.. (2024). The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab. Clinical and Experimental Medicine. 24(1). 111–111. 1 indexed citations

Jingushi, Kentaro, Atsunari Kawashima, Takuro Saito, et al.. (2024). Cutibacterium acnes‐derived extracellular vesicles promote tumor growth in renal cell carcinoma. Cancer Science. 115(8). 2578–2587. 13 indexed citations

10.

Oka, Toshitaka, Koji Hatano, Gaku Yamamichi, et al.. (2024). PSA Kinetics Affect Prognosis in Patients With Castration-resistant Prostate Cancer Treated With Enzalutamide. Cancer Diagnosis & Prognosis. 4(6). 706–714.

11.

Kato, Taigo, Eisuke Tomiyama, Yu Ishizuya, et al.. (2023). Prognostic significance of serum fucosylated pro-haptoglobin in advanced renal cell carcinoma patients treated with immune checkpoint inhibitors. Scientific Reports. 13(1). 17239–17239. 1 indexed citations

12.

Hatano, Koji, Akinaru Yamamoto, Toshihiro Uemura, et al.. (2022). The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer. International Journal of Clinical Oncology. 28(3). 427–435. 2 indexed citations

13.

Matsumoto, Fumi, Futoshi Matsui, Koji Yazawa, et al.. (2021). Bladder Cancer in a Long-term Survivor of the Prune Belly Syndrome. Urology. 161. 93–95. 1 indexed citations

14.

Kawashima, Atsunari, Yoshiyuki Yamamoto, Wataru Nakata, et al.. (2021). FAN score comprising fibrosis-4 index, albumin–bilirubin score and neutrophil–lymphocyte ratio is a prognostic marker of urothelial carcinoma patients treated with pembrolizumab. Scientific Reports. 11(1). 21199–21199. 13 indexed citations

15.

Hayashi, Yujiro, Kazutoshi Fujita, Kyosuke Matsuzaki, et al.. (2020). Clinical Significance of Hotspot Mutation Analysis of Urinary Cell-Free DNA in Urothelial Bladder Cancer. Frontiers in Oncology. 10. 755–755. 32 indexed citations

16.

Kato, Taigo, Eisuke Tomiyama, Yoko Koh, et al.. (2020). A Potential Mechanism of Anticancer Immune Response Coincident With Immune-related Adverse Events in Patients With Renal Cell Carcinoma. Anticancer Research. 40(9). 4875–4883. 9 indexed citations

17.

Fujita, Kazutoshi, Teruo Inamoto, Yu Ishizuya, et al.. (2017). Adjuvant chemotherapy improves survival of patients with high-risk upper urinary tract urothelial carcinoma: a propensity score-matched analysis. BMC Urology. 17(1). 110–110. 20 indexed citations

18.

Ishizuya, Yu, Koji Hatano, Yasutomo Nakai, et al.. (2016). [A Case of Renal Cell Carcinoma with Malignant Pleural Effusion Showing Marked Response to Axitinib].. Kyoto University Research Information Repository (Kyoto University). 62(10). 525–528. 1 indexed citations

19.

Ishizuya, Yu, Koji Hatano, Yasutomo Nakai, et al.. (2016). Desperation surgery for a chemorefractory lung lesion in a patient with an extragonadal germ cell tumor. International Cancer Conference Journal. 5(3). 154–157. 1 indexed citations

20.

Yamaguchi, Yuichiro, Yujiro Hayashi, Yu Ishizuya, et al.. (2014). A single-center study on predicting outcomes of primary androgen deprivation therapy for prostate cancer using the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score. Japanese Journal of Clinical Oncology. 45(2). 197–201. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact